Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 52 entries
Sorted by: Best Match Show Resources per page
Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study.

Advances and applications in bioinformatics and chemistry : AABC

Hasan TN, B LG, Masoodi TA, Shafi G, Alshatwi AA, Sivashanmugham P.
PMID: 21918635
Adv Appl Bioinform Chem. 2011;4:29-36. doi: 10.2147/AABC.S17371. Epub 2011 Mar 08.

BACKGROUND: The human progesterone receptor (hPR) belongs to the steroid receptor family. It may be found as monomers (A and B) and or as a dimer (AB). hPR is regarded as the prognostic biomarker for breast cancer. In a...

Cite
Hasan TN, B LG, Masoodi TA, et al. Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Adv Appl Bioinform Chem. 2011;4:29-36doi: 10.2147/AABC.S17371.
Hasan, T. N., B, L. G., Masoodi, T. A., Shafi, G., Alshatwi, A. A., & Sivashanmugham, P. (2011). Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Advances and applications in bioinformatics and chemistry : AABC, 429-36. https://doi.org/10.2147/AABC.S17371
Hasan, Tarique N, et al. "Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study." Advances and applications in bioinformatics and chemistry : AABC vol. 4 (2011): 29-36. doi: https://doi.org/10.2147/AABC.S17371
Hasan TN, B LG, Masoodi TA, Shafi G, Alshatwi AA, Sivashanmugham P. Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Adv Appl Bioinform Chem. 2011;4:29-36. doi: 10.2147/AABC.S17371. Epub 2011 Mar 08. PMID: 21918635; PMCID: PMC3169952.
Copy Download .nbib Format: NLM
Medical management of recurrent endometrioma with long-term norethindrone acetate.

International journal of women's health

Muneyyirci-Delale O, Anopa J, Charles C, Mathur D, Parris R, Cutler JB, Salame G, Abulafia O.
PMID: 22505834
Int J Womens Health. 2012;4:149-54. doi: 10.2147/IJWH.S27819. Epub 2012 Mar 30.

PURPOSE: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma.PATIENTS AND METHODS: Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological...

Cite
Muneyyirci-Delale O, Anopa J, Charles C, et al. Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Womens Health. 2012;4:149-54doi: 10.2147/IJWH.S27819.
Muneyyirci-Delale, O., Anopa, J., Charles, C., Mathur, D., Parris, R., Cutler, J. B., Salame, G., & Abulafia, O. (2012). Medical management of recurrent endometrioma with long-term norethindrone acetate. International journal of women's health, 4149-54. https://doi.org/10.2147/IJWH.S27819
Muneyyirci-Delale, Ozgul, et al. "Medical management of recurrent endometrioma with long-term norethindrone acetate." International journal of women's health vol. 4 (2012): 149-54. doi: https://doi.org/10.2147/IJWH.S27819
Muneyyirci-Delale O, Anopa J, Charles C, Mathur D, Parris R, Cutler JB, Salame G, Abulafia O. Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Womens Health. 2012;4:149-54. doi: 10.2147/IJWH.S27819. Epub 2012 Mar 30. PMID: 22505834; PMCID: PMC3325007.
Copy Download .nbib Format: NLM
The Management of Heavy Menstrual Bleeding After Percutaneous Coronary Intervention in a Woman of Reproductive Age.

Frontiers in pharmacology

Gu ZC, Shi FH, Zhu J, Wan F, Shen L, Li H.
PMID: 30697160
Front Pharmacol. 2019 Jan 15;9:1573. doi: 10.3389/fphar.2018.01573. eCollection 2018.

Heavy menstrual bleeding (HMB), previously known as menorrhagia, is in place with heavy flow and longer lasting days of bleeding during menstrual period, sequentially leading to anemia. We reported a rare case of HMB in a 33-year-old patient after...

Cite
Gu ZC, Shi FH, Zhu J, et al. The Management of Heavy Menstrual Bleeding After Percutaneous Coronary Intervention in a Woman of Reproductive Age. Front Pharmacol. 2019;9:1573doi: 10.3389/fphar.2018.01573.
Gu, Z. C., Shi, F. H., Zhu, J., Wan, F., Shen, L., & Li, H. (2018). The Management of Heavy Menstrual Bleeding After Percutaneous Coronary Intervention in a Woman of Reproductive Age. Frontiers in pharmacology, 91573. https://doi.org/10.3389/fphar.2018.01573
Gu, Zhi-Chun, et al. "The Management of Heavy Menstrual Bleeding After Percutaneous Coronary Intervention in a Woman of Reproductive Age." Frontiers in pharmacology vol. 9 (2018): 1573. doi: https://doi.org/10.3389/fphar.2018.01573
Gu ZC, Shi FH, Zhu J, Wan F, Shen L, Li H. The Management of Heavy Menstrual Bleeding After Percutaneous Coronary Intervention in a Woman of Reproductive Age. Front Pharmacol. 2019 Jan 15;9:1573. doi: 10.3389/fphar.2018.01573. eCollection 2018. PMID: 30697160; PMCID: PMC6341068.
Copy Download .nbib Format: NLM
Progestogen-only pills: which progestogen would be ideal.

Hormone molecular biology and clinical investigation

Egarter C.
PMID: 31922955
Horm Mol Biol Clin Investig. 2020 Jan 10;42(2):149-151. doi: 10.1515/hmbci-2019-0042.

Compared with nonuse, combined hormonal contraceptives containing estrogen and a progestogen are associated with a roughly 2- to 3-fold increased risk of venous and a 2-fold increased risk of arterial thromboembolism, including stroke and acute myocardial infarction. These events...

Cite
Egarter C. Progestogen-only pills: which progestogen would be ideal. Horm Mol Biol Clin Investig. 2020;42(2):149-151doi: 10.1515/hmbci-2019-0042.
Egarter, C. (2020). Progestogen-only pills: which progestogen would be ideal. Hormone molecular biology and clinical investigation, 42(2), 149-151. https://doi.org/10.1515/hmbci-2019-0042
Egarter, Christian. "Progestogen-only pills: which progestogen would be ideal." Hormone molecular biology and clinical investigation vol. 42,2 (2020): 149-151. doi: https://doi.org/10.1515/hmbci-2019-0042
Egarter C. Progestogen-only pills: which progestogen would be ideal. Horm Mol Biol Clin Investig. 2020 Jan 10;42(2):149-151. doi: 10.1515/hmbci-2019-0042. PMID: 31922955.
Copy Download .nbib Format: NLM
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.

American journal of obstetrics and gynecology

Al-Hendy A, Bradley L, Owens CD, Wang H, Barnhart KT, Feinberg E, Schlaff WD, Puscheck EE, Wang A, Gillispie V, Hurtado S, Muneyyirci-Delale O, Archer DF, Carr BR, Simon JA, Stewart EA.
PMID: 32702363
Am J Obstet Gynecol. 2021 Jan;224(1):72.e1-72.e50. doi: 10.1016/j.ajog.2020.07.032. Epub 2020 Jul 20.

BACKGROUND: Uterine fibroids are one of the most common neoplasms found among women globally, with a prevalence of approximately 11 million women in the United States alone. The morbidity of this common disease is significant because it is the...

Cite
Al-Hendy A, Bradley L, Owens CD, et al. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2020;224(1):72.e1-72.e50doi: 10.1016/j.ajog.2020.07.032.
Al-Hendy, A., Bradley, L., Owens, C. D., Wang, H., Barnhart, K. T., Feinberg, E., Schlaff, W. D., Puscheck, E. E., Wang, A., Gillispie, V., Hurtado, S., Muneyyirci-Delale, O., Archer, D. F., Carr, B. R., Simon, J. A., & Stewart, E. A. (2021). Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. American journal of obstetrics and gynecology, 224(1), 72.e1-72.e50. https://doi.org/10.1016/j.ajog.2020.07.032
Al-Hendy, Ayman, et al. "Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids." American journal of obstetrics and gynecology vol. 224,1 (2021): 72.e1-72.e50. doi: https://doi.org/10.1016/j.ajog.2020.07.032
Al-Hendy A, Bradley L, Owens CD, Wang H, Barnhart KT, Feinberg E, Schlaff WD, Puscheck EE, Wang A, Gillispie V, Hurtado S, Muneyyirci-Delale O, Archer DF, Carr BR, Simon JA, Stewart EA. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2021 Jan;224(1):72.e1-72.e50. doi: 10.1016/j.ajog.2020.07.032. Epub 2020 Jul 20. PMID: 32702363.
Copy Download .nbib Format: NLM
Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.

BMC women's health

Muhammad J, Yusof Y, Ahmad I, Norhayati MN.
PMID: 35033041
BMC Womens Health. 2022 Jan 15;22(1):14. doi: 10.1186/s12905-022-01596-2.

BACKGROUND: Elagolix is effective and safe for treating menorrhagia in women with uterine fibroid. However, it is reported to be associated with hypoestrogenism that can be alleviated by adding estradiol/norethindrone acetate. This systematic review and meta-analysis aimed to determine...

Cite
Muhammad J, Yusof Y, Ahmad I, et al. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis. BMC Womens Health. 2022;22(1):14doi: 10.1186/s12905-022-01596-2.
Muhammad, J., Yusof, Y., Ahmad, I., & Norhayati, M. N. (2022). Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis. BMC women's health, 22(1), 14. https://doi.org/10.1186/s12905-022-01596-2
Muhammad, Juliawati, et al. "Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis." BMC women's health vol. 22,1 (2022): 14. doi: https://doi.org/10.1186/s12905-022-01596-2
Muhammad J, Yusof Y, Ahmad I, Norhayati MN. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis. BMC Womens Health. 2022 Jan 15;22(1):14. doi: 10.1186/s12905-022-01596-2. PMID: 35033041.
Copy Download .nbib Format: NLM
Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.

The Annals of pharmacotherapy

Lynch SE, Mayer DC.
PMID: 33998300
Ann Pharmacother. 2022 Jan;56(1):93-101. doi: 10.1177/10600280211015987. Epub 2021 May 17.

OBJECTIVE: To review data of elagolix plus estradiol and norethindrone acetate as add-back therapy for the treatment of heavy menstrual bleeding (HMB) in premenopausal women with uterine fibroids.DATA SOURCES: Literature search of PubMed/MEDLINE and SCOPUS was performed using the...

Cite
Lynch SE, Mayer DC. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids. Ann Pharmacother. 2021;56(1):93-101doi: 10.1177/10600280211015987.
Lynch, S. E., & Mayer, D. C. (2022). Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids. The Annals of pharmacotherapy, 56(1), 93-101. https://doi.org/10.1177/10600280211015987
Lynch, Sarah E, and Mayer, Danielle C. "Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids." The Annals of pharmacotherapy vol. 56,1 (2022): 93-101. doi: https://doi.org/10.1177/10600280211015987
Lynch SE, Mayer DC. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids. Ann Pharmacother. 2022 Jan;56(1):93-101. doi: 10.1177/10600280211015987. Epub 2021 May 17. PMID: 33998300.
Copy Download .nbib Format: NLM
Unilateral Erythema Nodosum following Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate Combination Therapy.

Case reports in obstetrics and gynecology

Min MS, Fischer R, Fournier JB.
PMID: 27110414
Case Rep Obstet Gynecol. 2016;2016:5726416. doi: 10.1155/2016/5726416. Epub 2016 Mar 27.

Erythema nodosum is a septal panniculitis that typically presents as symmetric, tender nodules on the anterior aspects of bilateral lower extremities. Nearly half of cases are due to secondary causes, with oral contraceptive pills being the leading pharmaceutical cause....

Cite
Min MS, Fischer R, Fournier JB. Unilateral Erythema Nodosum following Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate Combination Therapy. Case Rep Obstet Gynecol. 2016;2016:5726416doi: 10.1155/2016/5726416.
Min, M. S., Fischer, R., & Fournier, J. B. (2016). Unilateral Erythema Nodosum following Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate Combination Therapy. Case reports in obstetrics and gynecology, 20165726416. https://doi.org/10.1155/2016/5726416
Min, Michelle S, et al. "Unilateral Erythema Nodosum following Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate Combination Therapy." Case reports in obstetrics and gynecology vol. 2016 (2016): 5726416. doi: https://doi.org/10.1155/2016/5726416
Min MS, Fischer R, Fournier JB. Unilateral Erythema Nodosum following Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate Combination Therapy. Case Rep Obstet Gynecol. 2016;2016:5726416. doi: 10.1155/2016/5726416. Epub 2016 Mar 27. PMID: 27110414; PMCID: PMC4826688.
Copy Download .nbib Format: NLM
A Case of Hemothorax as Manifestation of Thoracic Endometrial Syndrome.

Journal of investigative medicine high impact case reports

Patrucco Reyes S, Amoah K, Rahi MS, Gunasekaran K.
PMID: 34866438
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211052191. doi: 10.1177/23247096211052191.

Thoracic endometriosis is a rare progression of a mostly benign disease of ectopic endometrial activity involving the pleura and lung. This is a case of a young female who presented with progressive shortness of breath and was found to...

Cite
Patrucco Reyes S, Amoah K, Rahi MS, et al. A Case of Hemothorax as Manifestation of Thoracic Endometrial Syndrome. J Investig Med High Impact Case Rep. 2021;9:23247096211052191doi: 10.1177/23247096211052191.
Patrucco Reyes, S., Amoah, K., Rahi, M. S., & Gunasekaran, K. (2021). A Case of Hemothorax as Manifestation of Thoracic Endometrial Syndrome. Journal of investigative medicine high impact case reports, 923247096211052191. https://doi.org/10.1177/23247096211052191
Patrucco Reyes, Sandra, et al. "A Case of Hemothorax as Manifestation of Thoracic Endometrial Syndrome." Journal of investigative medicine high impact case reports vol. 9 (2021): 23247096211052191. doi: https://doi.org/10.1177/23247096211052191
Patrucco Reyes S, Amoah K, Rahi MS, Gunasekaran K. A Case of Hemothorax as Manifestation of Thoracic Endometrial Syndrome. J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211052191. doi: 10.1177/23247096211052191. PMID: 34866438; PMCID: PMC8652914.
Copy Download .nbib Format: NLM
Limb Amputation After Arterial Thromboembolism in a Patient Receiving Norethindrone.

The Annals of pharmacotherapy

Retamero Delgado A, Marín-Casino M, Jiménez Martínez C.
PMID: 28478714
Ann Pharmacother. 2017 Jun;51(6):516-517. doi: 10.1177/1060028017695612. Epub 2017 Feb 01.

No abstract available.

Cite
Retamero Delgado A, Marín-Casino M, Jiménez Martínez C. Limb Amputation After Arterial Thromboembolism in a Patient Receiving Norethindrone. Ann Pharmacother. 2017;51(6):516-517doi: 10.1177/1060028017695612.
Retamero Delgado, A., Marín-Casino, M., & Jiménez Martínez, C. (2017). Limb Amputation After Arterial Thromboembolism in a Patient Receiving Norethindrone. The Annals of pharmacotherapy, 51(6), 516-517. https://doi.org/10.1177/1060028017695612
Retamero Delgado, Alexandra, et al. "Limb Amputation After Arterial Thromboembolism in a Patient Receiving Norethindrone." The Annals of pharmacotherapy vol. 51,6 (2017): 516-517. doi: https://doi.org/10.1177/1060028017695612
Retamero Delgado A, Marín-Casino M, Jiménez Martínez C. Limb Amputation After Arterial Thromboembolism in a Patient Receiving Norethindrone. Ann Pharmacother. 2017 Jun;51(6):516-517. doi: 10.1177/1060028017695612. Epub 2017 Feb 01. PMID: 28478714.
Copy Download .nbib Format: NLM
Aqueous vaginal contrast and scheduled hematocolpos with magnetic resonance imaging to delineate complex müllerian anomalies.

Fertility and sterility

Romanski PA, Aluko A, Bortoletto P, Troiano RN, Pfeifer SM.
PMID: 34548169
Fertil Steril. 2022 Jan;117(1):221-223. doi: 10.1016/j.fertnstert.2021.08.041. Epub 2021 Sep 20.

OBJECTIVE: To demonstrate the advantage of using aqueous vaginal contrast and scheduled hematocolpos with magnetic resonance imaging (MRI) to improve the delineation of gynecologic anatomy and to recommend that this modality be considered in patients with complex müllerian anomalies.DESIGN:...

Cite
Romanski PA, Aluko A, Bortoletto P, et al. Aqueous vaginal contrast and scheduled hematocolpos with magnetic resonance imaging to delineate complex müllerian anomalies. Fertil Steril. 2021;117(1):221-223doi: 10.1016/j.fertnstert.2021.08.041.
Romanski, P. A., Aluko, A., Bortoletto, P., Troiano, R. N., & Pfeifer, S. M. (2022). Aqueous vaginal contrast and scheduled hematocolpos with magnetic resonance imaging to delineate complex müllerian anomalies. Fertility and sterility, 117(1), 221-223. https://doi.org/10.1016/j.fertnstert.2021.08.041
Romanski, Phillip A, et al. "Aqueous vaginal contrast and scheduled hematocolpos with magnetic resonance imaging to delineate complex müllerian anomalies." Fertility and sterility vol. 117,1 (2022): 221-223. doi: https://doi.org/10.1016/j.fertnstert.2021.08.041
Romanski PA, Aluko A, Bortoletto P, Troiano RN, Pfeifer SM. Aqueous vaginal contrast and scheduled hematocolpos with magnetic resonance imaging to delineate complex müllerian anomalies. Fertil Steril. 2022 Jan;117(1):221-223. doi: 10.1016/j.fertnstert.2021.08.041. Epub 2021 Sep 20. PMID: 34548169.
Copy Download .nbib Format: NLM
Adsorption of micropollutants present in surface waters onto polymeric resins: Impact of resin type and water matrix on performance.

The Science of the total environment

Haddad M, Oie C, Vo Duy S, Sauvé S, Barbeau B.
PMID: 30743938
Sci Total Environ. 2019 Apr 10;660:1449-1458. doi: 10.1016/j.scitotenv.2018.12.247. Epub 2019 Jan 11.

The occurrence of micropollutants in water resources is raising substantial concerns, worldwide. These pollutants may have adverse impacts on the aquatic ecosystem and human health. Even though activated carbon is commonly used as an adsorbent to remove micropollutants from...

Cite
Haddad M, Oie C, Vo Duy S, et al. Adsorption of micropollutants present in surface waters onto polymeric resins: Impact of resin type and water matrix on performance. Sci Total Environ. 2019;660:1449-1458doi: 10.1016/j.scitotenv.2018.12.247.
Haddad, M., Oie, C., Vo Duy, S., Sauvé, S., & Barbeau, B. (2019). Adsorption of micropollutants present in surface waters onto polymeric resins: Impact of resin type and water matrix on performance. The Science of the total environment, 6601449-1458. https://doi.org/10.1016/j.scitotenv.2018.12.247
Haddad, Maryam, et al. "Adsorption of micropollutants present in surface waters onto polymeric resins: Impact of resin type and water matrix on performance." The Science of the total environment vol. 660 (2019): 1449-1458. doi: https://doi.org/10.1016/j.scitotenv.2018.12.247
Haddad M, Oie C, Vo Duy S, Sauvé S, Barbeau B. Adsorption of micropollutants present in surface waters onto polymeric resins: Impact of resin type and water matrix on performance. Sci Total Environ. 2019 Apr 10;660:1449-1458. doi: 10.1016/j.scitotenv.2018.12.247. Epub 2019 Jan 11. PMID: 30743938.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 52 entries